MyRiskTM Hereditary Cancer Test

Meet MyRisk® with RiskScore®

Request more information or explore ordering options to bring MyRisk hereditary cancer testing to your practice.

Request information

Hereditary Cancer Risk Testing

More confident patient care begins with your patients’ genes

With the right hereditary cancer test, you can uncover valuable insights and answers that empower you and your patient to do more to help prevent cancer or diagnose it at an earlier, more treatable stage.

Hereditary cancer risk testing

More confident patient care begins with your patients’ genes

With the right hereditary cancer test, you can uncover valuable insights and answers that empower you and your patient to do more to help prevent cancer or diagnose it at an earlier, more treatable stage.

How high is your patient’s risk of developing cancer?

Knowing your patients’ hereditary cancer risk can dramatically impact the medical management decisions you make today.

Nearly 1 in 4 patients meet criteria for hereditary cancer testing1

MyRisk® Hereditary Cancer Test results, whether negative, positive, or elevated, can be used to your patients’ benefit. Combined with their personal and family history of cancer, the report will provide you with valuable information to effectively make decisions and manage patient cancer risk on an individual basis.

MyRiskTM Hereditary Cancer Test

MyRisk is more than a test

MyRisk with RiskScore® is a powerful tool that evaluates 48 genes associated with 11 different hereditary cancers. MyRisk helps any practice easily assess a patient’s lifetime hereditary cancer risk and help improve patient outcomes with expert guidance, support, and personalized care plans.

Designed for patients of all ancestries, RiskScore is a component of the MyRisk test that analyzes family history, personal clinical risk factors, and genetic markers to estimate the risk of developing breast cancer over the next five years and remaining lifetime.

Genetic insights with expert support

Our decades of genetic testing experience help you make confident and informed decisions with your patients. We provide personalized care plans based on each patient’s unique risk profile, and our team of experts is here to support you and your patient every step of the way.

Myriad Complete video playerplay video icon overlay

Myriad Complete

Your partner in patient care

We support patients and healthcare providers throughout the genetic testing process through pre-test education, transparent pricing and financial support, clear results reporting, and post-test education.

These solutions allow for simple integration of Myriad’s tests into routine clinical care and help patients better understand and benefit from their results.

MyRisk Patient Story

Forging a path forward

Lisa’s mom’s battle with breast cancer inspired her to get genetic testing and make a life-saving choice. Her story is a testament to courage and resilience.

Myriad’s commitment to you

Dedicated to making hereditary cancer testing affordable for all patients

Cost should never be a barrier when your patients need genetic testing to determine their risk reduction plan. It’s our promise to make testing accessible and affordable through options including:

Financial Assistance Program

Myriad’s Financial Assistance Program (MFAP) can help if your patients have a high deductible or co-insurance. With MFAP, they may qualify for $0 or reduced out-of-pocket cost, dependent on family size and income.

infographic showing 90% of patients pay $0
Broad insurance coverage

  • 95% of private insurance companies have coverage for hereditary cancer testing.2
  • 90% of patients pay $0 for testing2

Myriad Promise

Myriad Promise is our commitment to provide patients with access to accurate and affordable genetic results.

Related resources

0

MyRisk gene table

0

Documents & forms

0

Latest studies & publications

References:

  1. DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstetrics & Gynecology 2018 – published online before print October 10, 2018
  2. Internal Data, 2021
MyRiskTM Hereditary Cancer Test